Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4581263
Max Phase: Preclinical
Molecular Formula: C53H77N10O21P
Molecular Weight: 1221.22
Molecule Type: Unknown
Associated Items:
ID: ALA4581263
Max Phase: Preclinical
Molecular Formula: C53H77N10O21P
Molecular Weight: 1221.22
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)O)C(=O)N[C@@H](Cc1cc(=O)oc2cc(OP(=O)(O)O)ccc12)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(N)=O)C(C)C
Standard InChI: InChI=1S/C53H77N10O21P/c1-9-26(6)43(60-51(77)44(27(7)64)61-48(74)37-13-11-17-63(37)53(79)35(23-40(68)69)55-28(8)65)50(76)58-34(19-29-20-41(70)83-38-21-30(14-15-31(29)38)84-85(80,81)82)52(78)62-16-10-12-36(62)47(73)59-42(25(4)5)49(75)57-33(18-24(2)3)46(72)56-32(45(54)71)22-39(66)67/h14-15,20-21,24-27,32-37,42-44,64H,9-13,16-19,22-23H2,1-8H3,(H2,54,71)(H,55,65)(H,56,72)(H,57,75)(H,58,76)(H,59,73)(H,60,77)(H,61,74)(H,66,67)(H,68,69)(H2,80,81,82)/t26-,27+,32-,33-,34-,35-,36-,37-,42-,43-,44-/m0/s1
Standard InChI Key: LZYUDAFJZWUGSH-RGPAPDTMSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1221.22 | Molecular Weight (Monoisotopic): 1220.5002 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Ma ES, Barrios AM.. (2019) Rational design of a SHP-2 targeted, fluorogenic peptide substrate., 29 (17): [PMID:31351693] [10.1016/j.bmcl.2019.07.034] |
Source(1):